Hong Kong – Touyun Biotech won overwhelming shareholder support at its 5 June 2026 annual general meeting, with all 10 resolutions—nine ordinary and one special—passing by margins of at least 99.95 per cent of votes cast.

Key outcomes

1. Financial statements and director/auditor reports for the year ended 31 December 2025 were adopted with 1.26 billion votes in favour versus 0.10 million votes against (99.99 per cent approval).

2. Director appointments • Executive director Du Dong was re-elected unanimously (1.26 billion votes, 100 per cent). • Non-executive directors Chen Hui and Zhang Lele were each re-elected with 99.99 per cent support.

3. Remuneration and auditor matters • The board was authorised to set director remuneration (100 per cent approval). • Moore CPA Limited was re-appointed as independent auditor; the board may determine its fees (100 per cent approval).

4. Capital mandates • Directors received a 20 per cent general issuance mandate and a 10 per cent share-repurchase mandate. • An extension mandate allowing the issuance limit to rise by the volume of any shares repurchased was also approved. • Each capital mandate attracted 99.95 per cent shareholder support.

5. Bye-law overhaul • A special resolution adopting the second amended and restated bye-laws passed with 99.96 per cent in favour, exceeding the 75 per cent threshold required.

Additional details

• Shares in issue as of the meeting date totalled 2.81 billion. • No shareholders were required to abstain from voting under Hong Kong Listing Rules. • Tricor Investor Services served as scrutineer. • All directors attended the meeting except Wang Liang, who was absent due to other business commitments.

The decisive voting results grant Touyun Biotech’s board renewed flexibility in capital management and reinforce corporate governance structures through the newly adopted bye-laws.